This document provides an overview of GlaxoSmithKline (GSK), a large global pharmaceutical company. It discusses GSK's mission, values, strategic priorities, products, management structure, organizational chart, financial performance, and awards. Key information presented includes GSK's focus on growing through diversification, delivering more valuable products, simplifying operations, and building trust. The company's priorities, strengths, weaknesses, opportunities, and threats are also analyzed.

1. FTSE 100 COMPANY - GLAXOSMITHKLINE 1

2. GlaxoSmithKline
Presented by:-
Mr. Muhammad Ismail
Mr. Mohsin Yaseen
Mr.Abdus Sammad
Mr. Shahid
Mr . khizar Ali
Mr. Anil Kishore

3. TABLE OF CONTENT
 Acnowledgement
 Introducation
 Comapny Profile
 Executive Summary
 Mission , Values and Strategy history of GSK
 Gsk Products
 Management Level
 Gsk Organizational chart
 Performance
 Key Achievement
 Communication System
 Conclusion
 Reference
3

4. Acnowledgement
4
– First of all we would like to thank Almighty ALLAHA ,without His help we
would not able to accomplish this task.
– It would not be possible for us to accomplish this task without the help of
many individuals .We would like to thank our instructor of his course
(Org Business Communication) Sir Mozzam Shere ,who cooperated with
us in the case of quires and confusion .we have tried to fullest to fulfill
the requirement of the project that was assigned to us
– Sincerely
 Muhammad Ismail (10477)
 Abdu's Samad (10475)
 Mohsin Yaseen(10452)
 Khizar Ali (10521)
 Shahid (10520)
 Anil Kishore (10461)

5. Introducation
5
GSK, is a global pharmaceutical, biological, vaccines and
consumer healthcare company. It is the world's Six largest
pharmaceutical company measured by revenues (after
Johnson & Johnson, Pfizer & Roche
Company Profile :-
 Headquarter LONDON , UK
 Employee strength 96500
 Global operating countries over 206 countries
GSK was formed in 2000 by the merger of GlaxoWellcome plc
(formed from the acquisition of Wellcome plc by Glaxo plc),
and SmithKline Beecham plc (from the merger of Beecham
plc, and SmithKlineBeckman Corporation).

6. In Pakistan
6
GlaxoSmithKline Pakistan Limited came into existence after
the merger of Smith Kline and French of Pakistan Limited
and Beecham Pakistan (Private) Limited with Glaxo
Wellcome Pakistan Limited in 2002. It is listed on the
Karachi and Lahore stock exchanges. GSK has a large
portfolio of products ranging tablets, toothpaste, inhalers
and complex capsules in over 28,000 different pack sizes
and presentations.

7. HISTORY
7
GSK AT A GLANCE

8. Executive Summary
Chairman:
Sir Christopher Gent
Chief Executive Officer:
Andrew Witty
Pakistan Chief Executive Officer:
Salman Burney
FTSE 100 COMPANY - GLAXOSMITHKLINE 8

9. GSK MISSION
FTSE 100 COMPANY - GLAXOSMITHKLINE 9

10. GSK VISION
FTSE 100 COMPANY - GLAXOSMITHKLINE 10

11. GSK Values
FTSE 100 COMPANY - GLAXOSMITHKLINE 11
Respect for People
We believe that
respecting each other is
the key to
progress and growth for
our business, employees
and
customers. Our
employment practices
are designed to
create a culture, in which
all GSK employees feel
valued,
empowered and inspired
to achieve our goals
Patient Focused
Our commitment to our
purpose of improving the
lives
of billions ensures that all
our efforts, be it research,
manufacturing or
distribution are geared
towards
improving patient access
to quality health solutions.
Transparency
As our business evolves to
meet global challenges,
so do our existing systems
for which transparency is
integral. By being
transparent about what we
do and
how, we earn and build
trust.
Integrity
Our guiding principles go
beyond complying with legal
and ethical regulations. Each
member of the GSK family
takes pride in doing what is
right for the patients and
consumers, placing them at
the heart of every decision
we make. In doing so, we
demonstrate integrity in
action,
at every level, every day.

12. STRATEGIC PRIORITIES
FTSE 100 COMPANY - GLAXOSMITHKLINE 12
We are focused on the delivery of five strategic priorities to
achieve our mission of helping people “Do more, feel better,
live longer.”
Everyone at GSK has a role to play in delivering our
strategic priorities:
Grow a diversified, global business
Deliver more products of value
Create a culture of individual empowerment
Simplify the operating model
Building trust

13. GSK PRODUCTS
FTSE 100 COMPANY - GLAXOSMITHKLINE 13

14. GSK Vaccines
FTSE 100 COMPANY - GLAXOSMITHKLINE 14

15. CONSUMER HEALTHCARE PRODUCTS
FTSE 100 COMPANY - GLAXOSMITHKLINE 15

16. Management Level:
– The management levels of GSK are as follows:-
– Executive-Level
– Director-Level
– Manager-Level
– Staff
FTSE 100 COMPANY - GLAXOSMITHKLINE 16

17. GSK Organizational Chart
FTSE 100 COMPANY - GLAXOSMITHKLINE 17
Board of
Directors
Chairmain &
CEO
Deput
chairman
Executive
Directors
Marketing
Management
Dept.
Strategic
Management
Dept.
Product
Management
Dept.
Human
Resource
Dept.
Selection &
Recruitment
Dept.
Finance
Department
Audit Dept.
Quality
Controle
Dept.
Product Line
Q.C. Dept
Product Q.C.
Dept
Sales
Management
Dept.
National
Sales Dept.
Proviosional
Salels Dept.
Area Sales
Dept.
Trade Net
Dept.
International
Trade Ins.
General
Administratio
n Dept.
Planning &
Finance
Dept.
Overseas &
Domestic
Branch office
Advisory
Committee
on
Administratio
n
Development

18. FTSE 100 COMPANY - GLAXOSMITHKLINE 18
The economic environment in Pakistan witnessed some signs of recovery in 2014,
however many key challenges including the security situation, energy shortages &
government revenues remain formidable. The recent fall in global energy prices is
expected to have a positive impact on the economy and further strengthen growth and
reduce inflation in 2015.
During 2014, net sales of your Company were recorded at Rs 27.9 billion with double digit growth. Your
Company’s pharmaceutical business segment showed resilience by maintaining market share in the industry
and delivered net sales of Rs 23.0 billion reflecting a steady growth of 9.4% over last year. Key portfolios
contributing towards this growth were Eye/ear, Anti-Virals, Dermatological, Anthelmentics, Anti-Diarrhoeals,
Cough/ Cold and Respiratory. The Consumer Health Care set also evidenced strong growth of 16.3%
achieving an overall turnover of Rs 4.9 billion during 2014gmen. Sensodyne, Panadol and Horlicks were
the key growth drivers. During the year certain brands were realigned within business segments in line with
global strategy, which will help these products achieve better
growth and market penetration in the longer term
Performance

19. AWARDS FOR THE YEAR 2014
FTSE 100 COMPANY - GLAXOSMITHKLINE 19
Best Corporate Report Award
GSK Pakistan was awarded Certificate of Merit for
“Best Corporate Report Award 2013” in the Other/
Miscellaneous Sector. This award was presented
to GSK by The Joint Committee of The Institute of
Chartered Accountants of Pakistan (ICAP) and the
Institute of Cost and Management Accountants of
Pakistan (ICMAP). This award has been instrumental in
encouraging local companies to follow transparency in
preparing their annual reports according to international
best practices.
Environment Excellence Award
GSK Pakistan has been awarded “11th Annual
Environment
Excellence Award 2014” by the National Forum for
Environment and Health (NFEH). The award was given
on its outstanding contribution towards sustainable
development and in protecting the environment for
“Cleaner
& Greener Pakistan”. GSK was also given a special
recognition as an “Exemplary Leader TOP 10”.

20. SWOT ANALYSIS OF GSK PAKISTAN
FTSE 100 COMPANY - GLAXOSMITHKLINE 20
strength Threat
Weakness Oppotunity

21. SWOT ANALYSIS OF GSK PAKISTAN
FTSE 100 COMPANY - GLAXOSMITHKLINE 21
Strengths:
Strong Management Team
Large Market Share
Highest research Products in
Pakistan
Wide range of Products
Threats:
Lower cost competitors or imports like
Chinese and Indian medicines etc
Patent expiry on drugs that generate strong
income
Increasing cost of drug trials (research)
and ever higher standards imposed by
national drug approvals bodies.
Weaknesses:
No online presence in Pakistan
Strong focus on UK market (losing
opportunities in Pakistan)
Less checking on the sales
representatives for their working in
field
Opportunities:
Emerging markets and expansion
abroad
Have great chance to cash its brand
name in the field of surgical market
GSK can be able to cash its name in
baby foods

22. PORTER’S STRATEGIES
THE FIVE FORCES THAT SHAPE INDUSTRY COMPITITION
FTSE 100 COMPANY - GLAXOSMITHKLINE 22
RIVALAR
Y AMONG
EXISTING
COMPITIT
OR
THREAT
OF NEW
ENTRAN
TE
BARGINI
NG
POWER
OF
BUYER
THREAT
OF
SUBTIT
UTE
PRODU
CT OR
SERVIC
E
BARGIN
ING
POWER
OF
SUPPLI
ER

23. Planning application in gsk
– TO GROW A DIVERSIFIED GLOBAL BUSINESS.
– DELIVER VALUE PRODUCTS
– SIMPLIFYING THE OPERATING MODEL
– CHALLENGING AND INSPIRING MISSION
– LONG TERM INCENTIVE PLAN
FTSE 100 COMPANY - GLAXOSMITHKLINE 23

24. TO GROW A DIVERSIFIED GLOBAL
BUSINESS
Increase growth in the pharmaceutical business in its core
market.
GSK is diversifying its business to bring balance in product
portfolio & go away from a reliance on traditional markets.
GSK expects to generate future sales growth by
strengthening its core pharmaceutical business &
supplementing it with increased investment in growth such
as; vaccines, dermatology and consumer health care.
Business expansion inn Japan
Build a leadership in dermatology.
FTSE 100 COMPANY - GLAXOSMITHKLINE 24

25. Focusing on the best science
Focus on research and development
Diversifying the level of externalization in research
to focus on disease area, where GSK believe the
prospects for successful registration and launch of
differentiated medicines.
FTSE 100 COMPANY - GLAXOSMITHKLINE 25

26. SIMPLIFYING THE OPERATING MODEL
As GSK continue to change shape, so it is
essential that reduce the complexities in operating
model, improve efficiencies and reduce cost.
Re-shape manufacturing
FTSE 100 COMPANY - GLAXOSMITHKLINE 26

27. GSK has a challenging vision and
mission is to improve the quality of
human life by making people to do
more, feel better and live longer.
FTSE 100 COMPANY - GLAXOSMITHKLINE 27

28.  Long term incentive plan.
awards are made to executives under the following long
term incentive plan,
i) Deferred annual bonus plan
ii) Performance share plan
Explanation: Deferred Annual bonus plan:
The deferred annual bonus plan encourages long
term shareholding, discourages excessive risk taking and
help focus on GSK’S key strategic priorities
FTSE 100 COMPANY - GLAXOSMITHKLINE 28

29.  GlaxoSmithKline is the best world research pharmaceutical organization with high level
combination of resources & skills that provides strong growth in today fast change
healthcare environment market .
 GlaxoSmithKline are manufacturing ,developing and marketing of pharmaceutical and
consumer health related products
 GlaxoSmithKline’s has board of pharmaceutical product line includes antibiotics,
antidepressant ,gastrointestinal, dermatological ,respiratory ,cancer and cardiovascular
medications
 GlaxoSmithKline’s has wide variety of vaccine products including hepatitis A and B
,diphtheria taunts and whooping cough and influenza
 Bring oral healthcare ,over –the-counter medicines and nutritional healthcare products to
millions of people.
 In one sentence we can say that
 Gsk mission is to improve the quality of human life by enabling people to
do more, feel better and live longer
FTSE 100 COMPANY - GLAXOSMITHKLINE 29
CONCLUSION

30. REFERENCE
 GSK annual report 2014.
 www.gsk.com
 Wikipedia,2014
FTSE 100 COMPANY - GLAXOSMITHKLINE 30